Aurobindo Pharma Gets Final USFDA Nod for Azithromycin Oral Suspension | CORPORATE ETHOS

Aurobindo Pharma Gets Final USFDA Nod for Azithromycin Oral Suspension

By: | October 11, 2018
aurobindo
Oct 11: Drug maker Aurobindo Pharma Ltd on Thursday announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market its Azithromycin Oral Suspension 100
mg /5 mL and 200 mg/5 mL.
According to the company, Azithromycin oral suspension, is a generic version of Pfizer Inc’s Zithromax oral suspension. The product will be launched in November 2018, it said.
“Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections,” the company added.
The approved product has an estimated market size of $ 71 million for the twelve months ending August 2018, according to IQVIA.
This is the 125th ANDA (including 11 tentative approvals) to be approved out of Unit III formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 386 ANDA approvals (357 Final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from USFDA.